Immune cell clustering around tumor cells may precede tumor cell death, and may also occur independently, providing a rationale for combination studies (increase immune cell clustering plus cell death via checkpoint inhibition).
Molecules/cell therapies that work via different mechanisms of action (T-cells, monocytes, macrophages, NK cells, CAR-T) can be evaluated